Use este identificador para citar ou linkar para este item: http://hdl.handle.net/11690/2180
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorCaumo, Wolnei-
dc.contributor.authorHidalgo, Maria Paz-
dc.contributor.authorSouza, Andressa de-
dc.contributor.authorTorres, Iraci L. S.-
dc.contributor.authorAntunes, Luciana C.-
dc.date.accessioned2021-09-14T15:19:48Z-
dc.date.available2021-09-14T15:19:48Z-
dc.date.issued2019-
dc.identifier.citationCAUMO, W. et al. Melatonin is a biomarker of circadian dysregulation and is correlated with major depression and fibromyalgia symptom severity. Journal of Pain Research, v. 12, p. 545-556, 2019. Disponível em: https://www.dovepress.com/melatonin-is-a-biomarker-of-circadian-dysregulation-and-is-correlated--peer-reviewed-fulltext-article-JPR. Acesso em: 14 set. 2021.pt_BR
dc.identifier.urihttp://hdl.handle.net/11690/2180-
dc.description.abstractObjective: This study compared urinary 6-sulfatoxymelatonin (aMT6s) over 24 hours among fibromyalgia (FM), major depression disorder (MDD), and healthy control (HC) groups, and examined whether rhythm is correlated with depressive symptoms. To answer this question we compared the rhythm of urinary aMT6s secretion among each group in four time series: morning (06:00–12:00 hours), afternoon (12:00–18:00 hours), evening (18:00–24:00 hours), and night (24:00–06:00 hours). In the FM subjects, we assessed if the rhythm of urinary aMT6s secretion is associated with pain severity, sleep quality, number of trigger points (NTPs), and the pain pressure threshold (PPT). Patients and methods: We included 54 women, aged 18–60 years with diagnosis of FM (n=18), MDD (n=19), and HC (n =17). The 24-hour urinary aMT6s was evaluated according to four standardized periods. The assessment instruments were the Hamilton Depression Rating Scale (HDRS), Pittsburgh Sleep Quality Index, and Fibromyalgia Impact Questionnaire. Results: A generalized estimating equation revealed no difference in the daily load of aMT6s secretion among the three groups (P=0.49). However, at the daily time (06:00–18:00 hours), the load secretion of aMT6s reached 41.54% and 60.71% in the FM and MDD, respectively, as compared to 20.73% in the HC (P<0.05). A higher score in the HDRS was positively correlated with the amount of aMT6s secretion during daytime (06:00–18:00 hours). Also, multivariate linear regression revealed that in FM subjects, the aMT6s secretion during daytime (06:00–18:00 hours) was negatively correlated with the PPTlog (partial η2 =0.531, P=0.001). However, it was positively correlated with depressive symptoms (partial η2 =0.317, P=0.01); PQSI (partial η2 =0.306, P=0.017), and NTPs (partial η2 =0.23, P=0.04). Conclusion: A more significant load of aMT6s secretion during daytime hours was observed in MDD and FM subjects compared to HC. These findings help to comprehend the biological basis of these disorders and show how disruption in melatonin secretion is positively correlated with clinical symptoms.pt_BR
dc.language.isoen_USpt_BR
dc.publisherDovepresspt_BR
dc.rightsOpen Accessen_US
dc.subjectFibromyalgiapt_BR
dc.subjectDepressionpt_BR
dc.subjectPainpt_BR
dc.subjectMelatoninpt_BR
dc.subject6 sulfatoxymelatonin (aMT6s)pt_BR
dc.titleMelatonin is a biomarker of circadian dysregulation and is correlated with major depression and fibromyalgia symptom severitypt_BR
dc.typeArtigopt_BR
Aparece nas coleções:Artigo de Periódico (PPGSDH)

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
wcaumo.etal.pdfOpen Access456,71 kBAdobe PDFVisualizar/Abrir


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.